Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc, also known as Cosmos Health, is a global healthcare group engaged in innovative R&D, pharmaceuticals & nutraceuticals manufacturing, and healthcare product distribution. The company owns proprietary brands like Sky Premium Life and Mediterranation, providing a wide range of products to healthcare providers. In recent news, the acquisition of Pelofarm's pharmacy distribution network in Greece shows Cosmos Health's strategic expansion and revenue growth.
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) expects significant revenue growth from recent acquisitions, projecting a $12.5M increase in FY 2024 group revenue, with a gross profit of at least $3.1M and EBITDA in excess of $1.3M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
-
News
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced the acquisition of the license and rights for 'DIABIT-IS X', a generic drug used in the treatment of type-2 diabetes. The drug is set to be launched in Europe following the expiration of the patent for the branded drug 'Januvia'. Cosmos Health aims to capture a significant share of the European market and generate substantial profits from this investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.33%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO Greg Siokas plans to purchase up to $3 million in common shares through open market transactions, with $1 million already purchased in 2023. Siokas believes the shares are undervalued and intends to increase his stake by approximately 20% of the market capitalization. He has invested over $15 million in the company since inception and sees this as a strategic investment given the innovative R&D projects, AI-drug repurposing, planned spinoff of the R&D department, and international brand growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO to participate in Invest in Greece Forum, discussing investment opportunities in the healthcare sector. Registration and 1-on-1 meetings available for institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced an agreement with Cloudpharm PC to acquire the rights to repurpose a drug for treating various diseases, including CNS cancers and autoimmune diseases. The global brain tumor treatment market is expected to reach $3.1 billion by 2023, with a projected CAGR of 7.2% until 2033. Cosmos Health aims to explore drug repurposing opportunities using advanced technology to deliver medicines faster and more efficiently, targeting major health disorders like cancer, diabetes, and obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) filed a patent application with the European Patent Office for its CCX0722 obesity and weight management product, showcasing significant advancements and promising results in its R&D pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
Rhea-AI Summary
Cosmos Health Inc. (COSM) reported Q3 2023 revenues of $12.8M, a 7% increase YoY, with a solid balance sheet, but decreased gross margins and negative Adjusted EBITDA. The company also announced a strategic collaboration, a capital raise, and guidance to surpass $180M in gross annual revenue and $20M in EBITDA by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. announces acquisition of Cloudscreen®, an AI-powered platform for drug repurposing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. announces major strategic inflection point and strong financial position
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary
Cosmos Health Inc. plans to spin off its R&D division into a standalone biotech company, aiming to unlock shareholder value. The company has been investing in innovative R&D projects, including the CCX0722 product for obesity and weight management. Clinical trials for the product are scheduled to begin in Q4 2023. The spin-off decision is based on analysis of comparable biotech companies. Cosmos Health is also executing a buyback program to return capital to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.16%
Tags
FAQ
What is the current stock price of Cosmos Health (COSM)?
The current stock price of Cosmos Health (COSM) is $0.6165 as of February 21, 2025.
What is the market cap of Cosmos Health (COSM)?
The market cap of Cosmos Health (COSM) is approximately 14.6M.
What is Cosmos Health Inc known for?
Cosmos Health Inc is a global healthcare group engaged in R&D, pharmaceuticals & nutraceuticals manufacturing, and healthcare product distribution.
What proprietary brands does Cosmos Health Inc own?
Cosmos Health Inc owns proprietary brands like Sky Premium Life and Mediterranation.
What recent development has Cosmos Health Inc made?
Recent news includes the acquisition of Pelofarm's pharmacy distribution network in Greece, showcasing strategic expansion and revenue growth.
Where does Cosmos Health Inc operate?
Cosmos Health Inc is currently expanding throughout Europe, Asia, and North America, with offices and distribution centers in Thessaloniki, Athens, and Harlow.
How is Cosmos Health Inc leveraging technology in its operations?
Cosmos Health Inc utilizes advanced technological systems like A-Frame and ROWA in its facilities for automated procurement, inventory management, and order execution.
Cosmos Health Inc.
Nasdaq:COSM
COSM Rankings
COSM Stock Data
14.62M
18.81M
15.51%
10.28%
1.56%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
United States
THESSALONIKI